Loading
Gestational Diabetes Research and Management · Journal article
Obesity Surgery · September 5, 2026
Encouraging direction, but not yet definitive.
This prospective cohort study of 111 women with obesity and PMOS undergoing sleeve gastrectomy documents substantial metabolic and weight improvements sustained over 12 months, with group-based trajectory modeling identifying two postoperative weight loss patterns associated with different metabolic outcomes. The finding that greater weight loss correlates with better metabolic benefits is expected, but the inability of baseline characteristics to predict trajectory group suggests heterogeneous surgical response deserving further investigation.
Prospective cohort study with group-based trajectory modeling. Women with obesity and Polyendocrine Metabolic Ovarian Syndrome undergoing sleeve gastrectomy.. Intervention: Sleeve gastrectomy. n = 111.
Median BMI decreased from 38.5 kg/m² preoperatively to 26.7 kg/m² at 12 months, with median %TWL of 30.1% and %EWL of 83.9% HbA1c improved from 5.8% to 5.2% over 12 months Most pronounced changes in anthropometric and metabolic parameters occurred within the first three months
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The demonstration of substantial and sustained metabolic improvements across diverse outcomes (weight, glycemic control, lipids, insulin resistance) supports metabolic-bariatric surgery as an effective intervention in this metabolically complex population. However, the inability to predict which patients will follow an accelerated vs. normal weight loss trajectory from baseline characteristics suggests that postoperative management strategies may need to be individualized based on early response patterns rather than preoperative risk factors.
A single-center prospective cohort study with a modest sample size demonstrating clinically meaningful metabolic improvements and weight loss after bariatric surgery in a specific population, but lacking a comparator arm and with trajectories identified post-hoc by unsupervised modeling.
As stated by the source record.
Quoted from the source exactly as published.
The demonstration of substantial and sustained metabolic improvements across diverse outcomes (weight, glycemic control, lipids, insulin resistance) supports metabolic-bariatric surgery as an effective intervention in this metabolically complex population. However, the inability to predict which patients will follow an accelerated vs. normal weight loss trajectory from baseline characteristics suggests that postoperative management strategies may need to be individualized based on early response patterns rather than preoperative risk factors.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) is associated with substantial metabolic and reproductive burden. metabolic-bariatric surgery (MBS) is effective for weight loss, yet postoperative responses vary considerably. Identifying distinct weight loss trajectories and their associated metabolic outcomes may enable individualized postoperative management. In this prospective study, women with obesity and PMOS who underwent sleeve gastrectomy were followed at 1, 3, 6, and 12 months postoperatively. Group-based trajectory modeling (GBTM) based on percentage total weight loss (%TWL) was used to identify distinct patterns of weight loss. Longitudinal changes in anthropometric and metabolic parameters were compared between the identified trajectory groups. A total of 111 women were included. Significant improvements in anthropometric and metabolic parameters were observed over 12 months, with the most pronounced changes occurring within the first three months. Median BMI decreased from 38.5 kg/m. 2 preoperatively to 26.7 kg/m2 at 12 months (median %TWL 30.1%; %EWL 83.9%), and HbA1c improved from 5.8% to 5.2%. GBTM identified two distinct %TWL trajectories: an accelerated-decline group (57.7% of patients) and a normal-decline group (42.3%). Despite comparable baseline characteristics between the two groups, patients in the accelerated-decline group demonstrated consistently superior metabolic outcomes, including lower fasting insulin, C-peptide, and LDL-cholesterol at various postoperative time points. MBS yields substantial metabolic improvements in women with obesity and PMOS, with two distinct weight loss trajectories. Greater weight loss after MBS is associated with more pronounced metabolic benefits, yet preoperative characteristics do not distinguish between trajectory groups, underscoring the heterogeneity in surgical response and the need for further research into the determinants of differential outcomes. Significant improvements in HbA1c, fasting glucose, and HDL-C were observed within 3 months after MBS and sustained at 12 months. Two distinct %TWL trajectories were identified: an accelerated-decline group (57.7% of patients) and a normal-decline group (42.3%). Despite comparable baseline characteristics between the two groups, the accelerated-decline group demonstrated superior metabolic outcomes, including lower fasting insulin, C-peptide, and LDL-cholesterol.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.